Posted: October 16, 2014 at 1:44 am
Breakthrough in diabetes stem cell research
Doctors Jon LaPook and Holly Phillips join "CBS This Morning: Saturday" to discuss the week #39;s top medical news including a breakthrough in diabetes research ...
By: CBS This Morning
Visit link:
Breakthrough in diabetes stem cell research - Video
Posted: October 16, 2014 at 1:44 am
Vadodara city scientists #39; #39;Stem Cell #39; research could be boon for diabetics - Tv9 Gujarati
Vadodara: Stem cell research done by scientists based in the city may prove to be a boon for those diabetics, who are on insulin. The research aims to use stem cells extracted from body fat...
By: Tv9 Gujarati
Here is the original post:
Vadodara city scientists' 'Stem Cell' research could be boon for diabetics - Tv9 Gujarati - Video
Posted: October 15, 2014 at 6:58 pm
Stem Cell Therapy PennsylvaniaWorldstemcells.comis one of the leadingstem cell therapy and treatmentproviders for residents ofPennsylvaniaand across the nation. Our cutting edge technology and compassionate staff truly set us apart from the competition. We are a US based company that understands your needs and concerns when looking for a stem cell treatment center. Our treatment center is located in Cancun, Mexico.
Getting Started With Your Stem CellTherapy and Treatments Here at World Stem Cells LLC we try to make the process ofreceiving stem cell transplantsas easy as possible. We will help you figure out what your needs are and help you reach your goals as fast as possible. Follow the steps below on what to do.
Option 1 1.) Go to any page on our website and fill out the contact form. 2.) Fill in the required information and select the condition you would like to treat with stem cell therapy. 3.) Be sure to include any special information in the comments section. 4.)Click the submit button and we will contact you in a timely manner. 5.) Thats it, youre done!!!
REQUEST INFORMATION NOW!
Option 2
Call 800-234-1693 and speak with a representative regarding your stem cell therapy needs and requirements.
See the original post here:
Stem Cell Therapy Pennsylvania | Stem Cell Treatments
Posted: October 15, 2014 at 6:58 pm
PUBLIC RELEASE DATE:
15-Oct-2014
Holly Auer Penn Medicine 215-349-5659 215-200-2313 holly.auer@uphs.upenn.edu
Rachel Salis-Silverman Children's Hospital of Philadelphia 267-426-6063 267-970-3685 Salis@email.chop.edu
PHILADELPHIA Ninety percent of children and adults with acute lymphoblastic leukemia (ALL) who had relapsed multiple times or failed to respond to standard therapies went into remission after receiving an investigational personalized cellular therapy, CTL019, developed at the Perelman School of Medicine at the University of Pennsylvania. The results are published this week in The New England Journal of Medicine.
The new data, which builds on preliminary findings presented at the American Society of Hematology's annual meeting in December 2013, include results from the first 25 children and young adults (ages 5 to 22) treated at the Children's Hospital of Philadelphia and first five adults (ages 26 to 60) treated at the Hospital of the University of Pennsylvania. Twenty-seven of the 30 patients in the studies achieved a complete remission after receiving an infusion of these engineered "hunter" cells, and 78 percent of the patients were alive six months after treatment.
"The patients who participated in these trials had relapsed as many as four times, including 60 percent whose cancers came back even after stem cell transplants. Their cancers were so aggressive they had no treatment options left," said the study's senior author, Stephan Grupp, MD, PhD, a professor of Pediatrics in Penn's Perelman School of Medicine and director of Translational Research in the Center for Childhood Cancer Research at the Children's Hospital of Philadelphia. "The durable responses we have observed with CTL019 therapy are unprecedented."
Shannon Maude, MD, PhD, an assistant professor of Pediatrics and a pediatric oncologist at CHOP, and Noelle Frey, MD, MSCE, an assistant professor of Medicine and an oncologist at Penn's Abramson's Cancer Center, are co-first authors of the new study. The research team is led by Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research in the Abramson Cancer Center, along with David Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Blood and Marrow Transplantation in the Abramson Cancer Center.
CTL019 manufacturing begins with a patient's own T cells, which are collected via an apheresis process similar to blood donation, then reprogrammed in Penn's Clinical Cell and Vaccine Production Facility with a gene transfer technique that teaches the T cells to target and kill tumor cells. The engineered cells contain an antibody-like protein known as a chimeric antigen receptor (CAR), which is designed to bind to a protein called CD19 found on the surface of B cells, including the cancerous B cells that characterize several types of leukemia. The modified "hunter" cells are then infused back into the patient's body, where they both multiply and attack the cancer cells. A signaling domain built into the CAR promotes rapid multiplication of the "hunter" cells, building an army of tumor-killing cells that tests reveal can grow to more than 10,000 new cells for each single engineered cell patients receive.
Nineteen patients in the study remain in remission, 15 with this therapy alone, including a 9 year old who was the first ALL patient to receive the therapy more than two years ago. The follow-up periods reported in the study are more than six months for most patients, with a range from 1.4 to 24 months. Five patients went off-study for alternate therapy, three of whom proceeded to allogeneic stem cell transplants while in remission. Seven patients relapsed, between 6 weeks and 8.5 months after their infusions, including three whose cancers returned as CD19-negative leukemia that would not have been targeted by the modified cells.
See the article here:
Personalized cellular therapy achieves complete remission in 90 percent of acute lymphoblastic leukemia patients studied
Posted: October 15, 2014 at 6:51 pm
Knee arthritis 2.5 years after stem cell therapy by Harry Adelson, N.D.
Janet discusses her outcome three and a half years after bone marrow stem cell therapy by Dr Harry Adelson for her arthritic knees http://www.docereclinics.com.
By: Harry Adelson, N.D.
Read more from the original source:
Knee arthritis 2.5 years after stem cell therapy by Harry Adelson, N.D. - Video
Posted: October 15, 2014 at 6:49 pm
Vadodara city scientists #39; #39;Stem Cell #39; research could be boon for diabetics - Tv9 Gujarati
Vadodara: Stem cell research done by scientists based in the city may prove to be a boon for those diabetics, who are on insulin. The research aims to use stem cells extracted from body fat...
By: Tv9 Gujarati
Excerpt from:
Vadodara city scientists' 'Stem Cell' research could be boon for diabetics - Tv9 Gujarati - Video
Posted: October 15, 2014 at 6:49 pm
A treatment based on embryonic stem cells clears a key safety hurdle, and might help restore vision.
Transplanted cells appear as a dark spot on the retina of a person with macular degeneration.
When stem cells were first culled from human embryos 16 years ago, scientists imagined they would soon be treating diabetes, heart disease, stroke, and many other diseases with cells manufactured in the lab.
Its all taken longer than they thought. But today, a Massachusetts biotech firm reported results from the largest, and longest, human test of a treatment based on embryonic stem cells, saying it appears safe and may have partly restored vision to patients going blind from degenerative diseases.
Results of the three-year study were described today in the Lancet by Advanced Cell Technology and collaborating eye specialists at the Jules Stein Eye Institute in Los Angeles, who transplanted lab-grown cells into the eyes of nine people with macular degeneration and nine with Stargardts macular dystrophy.
The idea behind Advanced Cells treatment is to replace retinal pigment epithelium cells, known as RPE cells, a type of caretaker tissue without which a persons photoreceptors also die, with supplies grown in laboratory. It uses embryonic stem cells as a starting point, coaxing them to generate millions of specialized retina cells. In the study, each patient received a transplant of between 50,000 and 150,000 of those cells into one eye.
The main objective of the study was to prove the cells were safe. Beyond seeing no worrisome side effects, the researchers also noted some improvements in the patients. According to the researchers, half of them improved enough to read two to three extra lines on an eye exam chart. Robert Lanza, chief scientific officer of Advanced Cell, called these results remarkable.
We have people saying things no one would make up, like Oh I can see the pattern on my furniture, or now I drive to the airport, he says. Clearly there is something going on here.
Lanza stresses the need for a larger study, which he says the company hopes to launch later this year in Stargardts patients. But if the vision results seen so far continue, Lanza says, this would be a therapy.
Some eye specialists said its too soon to say whether the vision improvements were real. The patients werent examined by independent specialists, they said, and eyesight in patients with low vision is notoriously difficult to measure. That leaves plenty of room for placebo effects or unconscious bias on the part of doctors.
Originally posted here:
Stem Cells Seem Safe in Treating Eye Disease
Posted: October 15, 2014 at 6:49 pm
Published October 15, 2014
For the first time, researchers have created functioning human lung cells from stem cells.
The longest-running trial of stem cells derived from a human embryo found that the cells caused patients none of the problems scientists feared, such as forming tumors, and reversed partial blindness in about half the eyes receiving transplants, researchers reported on Tuesday.
The results, published in The Lancet, could help re-invigorate the controversial quest to harness stem cells, which have the ability to turn into any of the 200 kinds of human cells, to treat diseases.
In an accompanying commentary, Dr. Anthony Atala of the Wake Forest Institute for Regenerative Medicine called the work "a major accomplishment."
After intense excitement among scientists and the public about the promise of stem cells and ethical debates about destroying human embryos to obtain them, the field stumbled when a high-profile trial for spinal cord injury was halted by Geron Corp in 2011 and the interest of other companies waned.
The small study's main goal was assessing the safety of the transplanted cells. Called retinal pigment epithelial cells, they were created by taking stem cells from a days-old embryo created in a fertility clinic and inducing them to differentiate into the specialized cells.
The study "provides the first evidence, in humans with any disease, of the long-term safety and possible biologic activity" of cells derived from embryos, said co-author Dr. Robert Lanza, chief scientific officer of Advanced Cell Technology, which produced the cells and funded the study.
Nine patients with Stargardt's disease (which causes macular degeneration in childhood) and nine with dry age-related macular degeneration (a leading cause of adult blindness) received implants of the retinal cells in one eye. The other eye served as a control.
Four eyes developed cataracts and two became inflamed, probably due to the patients' age (median: 77) or the use of immune-supressing transplant drugs.
Read the rest here:
Stem cells from human embryos prove safe, improve vision, study says
Posted: October 15, 2014 at 6:49 pm
Powerful stem cells injected into the eyes of 18 patients with diseases causing progressive blindness have proven safe and dramatically improved the vision of some of the patients, scientists report.
Three years of follow up show that vision improved measurably in seven of the patients, the team at Advanced Cell Technology report in the Lancet medical journal. In some cases, the improvement was dramatic.
For instance, we treated a 75-year-old horse rancher who lives in Kansas, said Dr. Robert Lanza, chief medical officer for the Massachusetts-based company. The rancher had poor vision 20/400 in one eye.
Once month after treatment his vision had improved 10 lines (20/40) and he can even ride his horses again. Other patients report similarly dramatic improvements in their lives, Lanza added. For instance, they can use their computers or read their watch. Little things like that which we all take for granted have made a huge difference in the quality of their life.
Not all the patients improved and one even got worse. But overall, Lanzas team reported, the patients vision improved by three lines on a standard vision chart.
"They can use their computers or read their watch. Little things like that which we all take for granted have made a huge difference in the quality of their life.
The researchers treated only one eye in each patient. There was no improvement in vision in the untreated eyes.
The patients had either Stargardts disease, a common type of macular degeneration, or dry macular degeneration, which is the leading cause of blindness in the developed world. There are no treatments for either condition, and patients gradually lose vision over the years until they are, often, blind.
Lanzas team used human embryonic stem cells, made using human embryos. They are powerful cells, each one capable of giving rise to all the cells and tissues in the body. The ACT team took one cell from embryos at the eight-cell stage to make batches of these cells.
They reprogrammed them to make immature retinal cells, which they injected into the eyes of the patients. The hope is that the immature cells would take up the places of the degenerated cells and restore vision.
Visit link:
Vision Quest: Stem Cells Treat Blinding Disease
Posted: October 15, 2014 at 6:49 pm
Dr. Deepak Srivastava, a leading biomedical research policy expert, will discuss "Stem Cells, Regenerative Medicine and Policy Impediments to the New Future" at Rice University's Baker Institute for Public Policy Oct. 21. The event is free and open to the public, but registration is required.
Who: Dr. Deepak Srivastava, the Baker Institute's nonresident scholar for biomedical research policy and the Younger Family Director and senior investigator at the Gladstone Institute of Cardiovascular Disease.
Neal Lane, the Malcolm Gillis University Professor, senior fellow in science and technology policy at Rice's Baker Institute for Public Policy and a professor of physics and astronomy, will give introductory remarks.
What: A presentation titled "Stem Cells, Regenerative Medicine and Policy Impediments to the New Future."
When: Tuesday, Oct. 21, 7:45-9:30 a.m. Breakfast will be served at 7:45.
Where: Rice University, James A. Baker III Hall, Kelly International Conference Facility, 6100 Main St.
Stem cells and regenerative medicine are exciting and emerging fields of biomedical research, according to event organizers. Proposed applications include treating conditions such as blindness, diabetes and heart disease. Regenerative medicine could also help heal failing organ systems and replace damaged tissue. While these fields hold great promise for medicine, external factors limit and, in some cases, stall research, organizers said. Ethical controversies surrounding human embryonic stem cells, policy issues affecting federal and state funding and regulation, and economic pressures all play a role in determining the future of research.
In his presentation, Srivastava will explore the current and future potential of stem cells and regenerative medicine. Following the presentation, he will discuss policy challenges and opportunities with Lane.
The event is sponsored by the Baker Institute's Science and Technology Policy Program and the Health Policy Forum.
Read the original post:
Policy impediments to using stem cells and regenerative medicine to be discussed at Rice's Baker Institute Oct. 21
